112887-68-0 | Raltitrexed

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$12.00	$8.00
10mg	95%	in stock	$33.00	$23.00
25mg	95%	in stock	$39.00	$27.00
50mg	95%	in stock	$58.00	$40.00
100mg	95%	in stock	$69.00	$48.00
250mg	95%	in stock	$154.00	$108.00
1g	95%	in stock	$369.00	$259.00
5g	95%	in stock	$1,463.00	$1,024.00

Description

• Catalog Number: AB51386
• Chemical Name: Raltitrexed
• CAS Number: 112887-68-0
• Molecular Formula: C21H22N4O6S
• Molecular Weight: 458.4876
• MDL Number: MFCD12828867
• SMILES: OC(=O)CC[C@@H](C(=O)O)NC(=O)c1ccc(s1)N(CC1C=CC2=NC(=NC(=O)C2=C1)C)C
• NSC Number: 639186

Computed Properties

• Complexity: 790
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 32
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 9
• XLogP3: 1.4

Literature

• Diffuse malignant peritoneal mesothelioma--an update on treatment.

  Cancer treatment reviews 20121001

• Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer.

  International journal of cancer 20120915

• A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20120801

• Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.

  Bioorganic & medicinal chemistry 20120715

• Influence of resistance to 5-fluorouracil and tomudex on [18F]‑FDG incorporation, glucose transport and hexokinase activity.

  International journal of oncology 20120701

• Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.

  British journal of pharmacology 20120501

• Systemic treatment of malignant pleural mesothelioma.

  Future oncology (London, England) 20120301

• Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.

  Lung cancer (Amsterdam, Netherlands) 20120201

• Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1).

  Molecular pharmacology 20120201

• Folic acid supplementation increases survival and modulates high risk HPV-induced phenotypes in oral squamous cell carcinoma cells and correlates with p53 mRNA transcriptional down-regulation.

  Cancer cell international 20120101

• Constitutive and treatment-induced CXCL8-signalling selectively modulates the efficacy of anti-metabolite therapeutics in metastatic prostate cancer.

  PloS one 20120101

• In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma.

  Toxicology in vitro : an international journal published in association with BIBRA 20111201

• Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies.

  Annals of surgical oncology 20111201

• Affinity characterization-mass spectrometry methodology for quantitative analyses of small molecule protein binding in solution.

  Analytical biochemistry 20111101

• Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase II study.

  Acta oncologica (Stockholm, Sweden) 20111101

• Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase.

  Journal of medicinal chemistry 20111027

• A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143).

  Investigational new drugs 20111001

• Raltitrexed in mesothelioma.

  Expert review of anticancer therapy 20111001

• Pathways of resistance to thymineless death in Escherichia coli and the function of UvrD.

  Genetics 20110901

• Inhibitor-bound complexes of dihydrofolate reductase-thymidylate synthase from Babesia bovis.

  Acta crystallographica. Section F, Structural biology and crystallization communications 20110901

• SEOM guidelines for the treatment of malignant pleural mesothelioma.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20110801

• PEA3/ETV4-related transcription factors coupled with active ERK signalling are associated with poor prognosis in gastric adenocarcinoma.

  British journal of cancer 20110628

• Thiothymidine combined with UVA as a potential novel therapy for bladder cancer.

  British journal of cancer 20110607

• Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.

  The pharmacogenomics journal 20110601

• Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.

  British journal of cancer 20110510

• MicroRNA dysregulation in colorectal cancer: a clinical perspective.

  British journal of cancer 20110315

• Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: long-term outcome.

  International journal of radiation oncology, biology, physics 20110301

• Value of ADC measurements for nodal staging after chemoradiation in locally advanced rectal cancer-a per lesion validation study.

  European radiology 20110201

• Adjuvant chemotherapy for localised colon cancer. Fluorouracil + folinic acid for node-positive, non-metastatic disease.

  Prescrire international 20110201

• Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.

  British journal of cancer 20110118

• Human thymidylate synthase with loop 181-197 stabilized in an inactive conformation: ligand interactions, phosphorylation, and inhibition profiles.

  Protein science : a publication of the Protein Society 20110101

• Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study.

  BMC medical research methodology 20110101

• GTI: a novel algorithm for identifying outlier gene expression profiles from integrated microarray datasets.

  PloS one 20110101

• Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of gastric cancer with peritoneal carcinomatosis: evidence from an experimental study.

  Journal of translational medicine 20110101

• Heath-related quality of life in thyroid cancer patients following radioiodine ablation.

  Health and quality of life outcomes 20110101

• An unusual presentation of multiple cavitated lung metastases from colon carcinoma.

  BMC medical imaging 20110101

• Expression of RFC/SLC19A1 is associated with tumor type in bladder cancer patients.

  PloS one 20110101

• A 26-year-old male with mesothelioma due to asbestos exposure.

  Case reports in medicine 20110101

• Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma.

  Therapeutics and clinical risk management 20110101

• Clinical characteristics and treatment outcomes in 132 patients with malignant mesothelioma.

  Lung India : official organ of Indian Chest Society 20110101

• The state of research into children with cancer across Europe: new policies for a new decade.

  Ecancermedicalscience 20110101

• Investigational approaches for mesothelioma.

  Frontiers in oncology 20110101

• Phenotypic enhancement of thymidylate synthetase pathway inhibitors following ablation of Neil1 DNA glycosylase/lyase.

  Cell cycle (Georgetown, Tex.) 20101215

• Antifolate inhibitors of thymidylate synthase as anticancer drugs.

  Mini reviews in medicinal chemistry 20101101

• Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).

  Gut 20101101

• Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.

  British journal of cancer 20101101

• Substrate-specific binding and conformational changes involving Ser313 and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking.

  The Biochemical journal 20100901

• Identification of thymidylate synthase as a potential therapeutic target for lung cancer.

  British journal of cancer 20100727

• Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.

  British journal of cancer 20100727

• Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study.

  Anti-cancer drugs 20100701

• Characterisation of the bifunctional dihydrofolate synthase-folylpolyglutamate synthase from Plasmodium falciparum; a potential novel target for antimalarial antifolate inhibition.

  Molecular and biochemical parasitology 20100701

• Pyridinium 5-nitro-thio-phene-2-carboxyl-ate.

  Acta crystallographica. Section E, Structure reports online 20100601

• The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy.

  British journal of cancer 20100202

• [Prerequisites to the administration and prevention of adverse effects of chemotherapy in colorectal cancer].

  Bulletin du cancer 20100201

• Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status.

  British journal of cancer 20100119

• Colorectal cancer: response to sunitinib in a heavily pretreated colorectal cancer patient.

  Anti-cancer drugs 20100101

• Synthesis and biological activity of raltitrexed-carrier conjugates.

  Acta biochimica Polonica 20100101

• Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells.

  Molecular cancer 20100101

• Interaction between thymidylate synthase and its cognate mRNA in zebrafish embryos.

  PloS one 20100101

• Analysis of the thymidylate synthase gene structure in colorectal cancer patients and its possible relation with the 5-Fluorouracil drug response.

  Journal of nucleic acids 20100101

• Molecular docking studies on quinazoline antifolate derivatives as human thymidylate synthase inhibitors.

  Bioinformation 20100101

• The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma.

  Molecular cancer 20100101

• CoFactor: Folate Requirement for Optimization of 5-Fluouracil Activity in Anticancer Chemotherapy.

  Journal of oncology 20100101

• Cancer chemotherapy: targeting folic acid synthesis.

  Cancer management and research 20100101

• Raltitrexed: optimism and reality.

  Expert opinion on drug metabolism & toxicology 20091101

• Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.

  Cancer chemotherapy and pharmacology 20091001

• Malignant pleural mesothelioma: an update on biomarkers and treatment.

  Chest 20090901

• Adjuvant chemotherapy for stages II, III and IV of colon cancer.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20090801

• Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials.

  British journal of cancer 20090707

• C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.

  European journal of cancer (Oxford, England : 1990) 20090501

• Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed.

  Cancer biology & therapy 20090501

• Future developments in the management of malignant pleural mesothelioma.

  Expert review of anticancer therapy 20090401

• Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090320

• Chiral separation of raltitrexed by cyclodextrin-modified micellar electrokinetic chromatography.

  Analytical and bioanalytical chemistry 20090101

• Late cutaneous metastases to the face from malignant pleural mesothelioma: a case report and review of the literature.

  World journal of surgical oncology 20090101

• Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma.

  Journal of gastrointestinal cancer 20090101

• An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinical benefit - PANUSCO.

  BMC cancer 20090101

• APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.

  BMC cancer 20090101

• Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008.

  Health and quality of life outcomes 20090101

• Outcome for esophageal cancer following treatment with chemotherapy and radiotherapy but not esophagectomy: Nonsurgical treatment of esophageal cancer.

  Clinical and experimental gastroenterology 20090101

• Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.

  Cancer chemotherapy and pharmacology 20081101

• DNA damage and homologous recombination signaling induced by thymidylate deprivation.

  Biochemical pharmacology 20081015

• Induction of intrachromosomal homologous recombination in human cells by raltitrexed, an inhibitor of thymidylate synthase.

  DNA repair 20081001

• Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).

  European journal of cancer (Oxford, England : 1990) 20081001

• The confused cancer patient: a case of 5-fluorouracil-induced encephalopathy.

  Current oncology (Toronto, Ont.) 20081001

• The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier.

  Molecular pharmacology 20080901

• Inequity in colorectal cancer treatment and outcomes: a population-based study.

  British journal of cancer 20080722

• EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality.

  British journal of cancer 20080708

• Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.

  British journal of cancer 20080708

• Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma.

  British journal of cancer 20080708

• Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes.

  Molecular microbiology 20080701

• A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.

  Nature clinical practice. Urology 20080701

• [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].

  Zentralblatt fur Chirurgie 20080601

• Systemic treatments for mesothelioma: standard and novel.

  Current treatment options in oncology 20080601

• Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women.

  British journal of cancer 20080506

• Low expression of gamma-glutamyl hydrolase mRNA in primary colorectal cancer with the CpG island methylator phenotype.

  British journal of cancer 20080506

• The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20080501

• Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.

  Lancet (London, England) 20080501

• Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a phase I/II study.

  British journal of cancer 20080408

• Current concepts in chemotherapy for malignant pleural mesothelioma.

  The clinical respiratory journal 20080401

• Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.

  Lancet (London, England) 20080322

• Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy.

  International journal of radiation oncology, biology, physics 20080201

• Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase.

  DNA repair 20080201

• Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II.

  Anti-cancer agents in medicinal chemistry 20080201

• Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma.

  Therapeutics and clinical risk management 20080201

• Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer.

  Bulletin of experimental biology and medicine 20080201

• Chronic myeloid leukemia following the treatment of rectal adenocarcinoma.

  Medical oncology (Northwood, London, England) 20080101

• Kinetics and ligand-binding preferences of Mycobacterium tuberculosis thymidylate synthases, ThyA and ThyX.

  PloS one 20080101

• Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability.

  Journal of translational medicine 20080101

• What oncologists tell patients about survival benefits of palliative chemotherapy and implications for informed consent: qualitative study.

  BMJ (Clinical research ed.) 20080101

• Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease.

  BMC neuroscience 20080101

• Intranasal administration of acetylcholinesterase inhibitors.

  BMC neuroscience 20080101

• Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study.

  Journal of occupational medicine and toxicology (London, England) 20080101

• Malignant mesothelioma.

  Orphanet journal of rare diseases 20080101

• Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer.

  Journal of gastrointestinal cancer 20080101

• A retrospective comparison of concurrent bolus 5-fluorouracil or raltitrexed in preoperative chemoradiation for locally advanced rectal cancer.

  Hematology/oncology and stem cell therapy 20080101

• Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071220

• In Australia, patients and government at odds over mesothelioma treatment costs.

  Journal of the National Cancer Institute 20071205

• Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.

  Cancer investigation 20071201

• Progression-free survival is a surrogate for survival in advanced colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071120

• Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules.

  British journal of cancer 20071022

• [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.

  British journal of cancer 20071008

• Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group.

  Annals of surgical oncology 20071001

• Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: part I.

  Anti-cancer agents in medicinal chemistry 20070901

• Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.

  Investigational new drugs 20070801

• Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.

  Anti-cancer drugs 20070801

• Therapy of colon carcinoma: an oncology perspective. Interview with Piotr M. Czaykowski by Paul C. Adams.

  Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20070801

• Combination silencer RNA (siRNA) targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines.

  The Journal of pharmacology and experimental therapeutics 20070701

• Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition.

  Oncology reports 20070701

• [Myocardial ischaemia as a result of treatment with capecitabine].

  Nederlands tijdschrift voor geneeskunde 20070630

• Determination of raltitrexed in human plasma by high performance liquid chromatography-electrospray ionization-mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070615

• A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer.

  Expert opinion on pharmacotherapy 20070601

• A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.

  British journal of cancer 20070507

• Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks.

  Cancer chemotherapy and pharmacology 20070501

• Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials.

  British journal of cancer 20070326

• Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients.

  British journal of cancer 20070312

• Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels.

  British journal of cancer 20070312

• An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed.

  Cancer chemotherapy and pharmacology 20070201

• Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.

  Oncology reports 20070201

• Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment.

  British journal of cancer 20070129

• Antisense targeting of thymidylate synthase (TS) mRNA increases TS gene transcription and TS protein: effects on human tumor cell sensitivity to TS enzyme-inhibiting drugs.

  Gene expression 20070101

• Cost considerations in the treatment of colorectal cancer.

  PharmacoEconomics 20070101

• Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients.

  World journal of surgical oncology 20070101

• Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.

  Molecular cancer 20070101

• Effects of antifolate drugs on the cellular uptake of radiofolates in vitro and in vivo.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20061201

• Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer.

  British journal of cancer 20061106

• Biology and management of malignant pleural mesothelioma.

  European journal of cancer (Oxford, England : 1990) 20061101

• St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis.

  Toxicology and applied pharmacology 20061015

• Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines.

  British journal of cancer 20061009

• Raltitrexed and pemetrexed studies in mesothelioma have not shown improved quality of life nor prolonged survival compared with effective pleurodesis with thoracoscopic talc poudrage.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061001

• A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours.

  British journal of cancer 20060918

• A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.

  British journal of cancer 20060904

• ['Iatrogenic acute coronary syndrome'--59 year old patient with adenocarcinoma of ascending colon and stenocardia while receiving adjuvant chemotherapy with 5-fluorouracil].

  Zeitschrift fur Gastroenterologie 20060901

• Systemic chemotherapy in the management of malignant peritoneal mesothelioma.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20060801

• First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060801

• A proposed clinical test for monitoring fluoropyrimidine therapy: detection and stability of thymidylate synthase ternary complexes.

  Cancer biology & therapy 20060801

• 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20060801

• The combination of raltitrexed (Tomudex) and mitomycin-C in the treatment of advanced colorectal cancer--a phase II study.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20060801

• Severe enteropathy associated with raltitrexed and oxaliplatin chemotherapy: report of two patients experiencing this rare, potentially lethal gastrointestinal adverse event.

  Anti-cancer drugs 20060801

• The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.

  British journal of cancer 20060703

• The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060701

• Computer modelling of antifolate inhibition of folate metabolism using hybrid functional petri nets.

  Journal of theoretical biology 20060621

• Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study.

  British journal of cancer 20060619

• Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060601

• Adding raltitrexed to cisplatin improves overall survival in people with malignant pleural mesothelioma.

  Cancer treatment reviews 20060501

• XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.

  British journal of cancer 20060410

• Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.

  Expert opinion on pharmacotherapy 20060401

• Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.

  British journal of cancer 20060327

• Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060320

• Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.

  International journal of radiation oncology, biology, physics 20060315

• Quantitative structure-pharmacokinetic relationships for drug clearance by using statistical learning methods.

  Journal of molecular graphics & modelling 20060301

• Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.

  Cancer 20060301

• Role of N-terminal residues in the ubiquitin-independent degradation of human thymidylate synthase.

  The Biochemical journal 20060215

• The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line.

  Molecular cancer therapeutics 20060201

• Antimetabolites and cancer: emerging data with a focus on antifolates.

  Expert opinion on therapeutic patents 20060201

• Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.

  Cancer chemotherapy and pharmacology 20060101

• Study on brain targeting of raltitrexed following intranasal administration in rats.

  Cancer chemotherapy and pharmacology 20060101

• A National Cancer Institute of Canada Clinical Trials Group Study--IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20060101

• Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer.

  Neoplasma 20060101

• Analysis of folylpoly-gamma-glutamate synthetase gene expression in human B-precursor ALL and T-lineage ALL cells.

  BMC cancer 20060101

• Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.

  Oncology 20060101

• Pre-operative radiochemotherapy with raltitrexed for resectable locally-advanced rectal cancer: a phase II study.

  Anticancer research 20060101

• The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20060101

• Metachronic malignant transformation of small bowel and rectal endometriosis in the same patient.

  World journal of surgical oncology 20060101

• Financial considerations in the conduct of multi-centre randomised controlled trials: evidence from a qualitative study.

  Trials 20060101

• Oxaliplatin with raltitrexed and preoperative radiotherapy in T3-T4 extraperitoneal rectal cancer. A dose finding study.

  Tumori 20060101

• [A review of chemotherapy for metastatic colon cancer].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20060101

• Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.

  Oncology 20060101

• [Mesothelioma: advances in chemotherapy].

  Revue des maladies respiratoires 20051201

• Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.

  Prescrire international 20051201

• Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.

  Prescrire international 20051201

• Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.

  British journal of cancer 20051128

• Determination of apoptosis, uracil incorporation, DNA strand breaks, and sister chromatid exchanges under conditions of thymidylate deprivation in a model of BER deficiency.

  Biochemical pharmacology 20051115

• A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study.

  British journal of cancer 20051031

• A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies.

  British journal of cancer 20051017

• Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051001

• Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.

  Cancer research 20051001

• ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates.

  Cancer research 20050915

• Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.

  British journal of cancer 20050905

• Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy.

  Clinical colorectal cancer 20050901

• Overview on ongoing or planned clinical trials in Europe.

  Lung cancer (Amsterdam, Netherlands) 20050701

• Enhancement of 5-fluorouracil sensitivity by an rTS signaling mimic in H630 colon cancer cells.

  Cancer research 20050701

• Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.

  Lung cancer (Amsterdam, Netherlands) 20050601

• A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.

  Cancer research 20050601

• The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20050501

• [Development in the treatment of malignant mesothelioma].

  Nederlands tijdschrift voor geneeskunde 20050402

• Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study.

  British journal of cancer 20050328

• Chemotherapy options and new advances in malignant pleural mesothelioma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050301

• Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050301

• DNA mismatch repair-dependent response to fluoropyrimidine-generated damage.

  The Journal of biological chemistry 20050218

• A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma.

  British journal of cancer 20050214

• Characterization of binding of folates and antifolates to brush-border membrane vesicles isolated from human kidney.

  Molecular pharmacology 20050201

• Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98).

  Investigational new drugs 20050101

• ZD9331: discovery to clinical development.

  Anti-cancer drugs 20050101

• A study of the effect of temperature on the pharmacokinetic profile of raltitrexed administered by intraperitoneal route in the rat.

  Medical science monitor : international medical journal of experimental and clinical research 20050101

• Novel chemical strategies for thymidylate synthase inhibition.

  Current medicinal chemistry 20050101

• Synergistic antitumor activity of capecitabine in combination with irinotecan.

  Clinical colorectal cancer 20050101

• Importance of preclinical investigations of the integration of capecitabine into polychemotherapy regimens.

  Clinical colorectal cancer 20050101

• Phase I study of concomitant chemoradiation with raltitrexed in locally advanced head and neck cancer.

  European journal of cancer (Oxford, England : 1990) 20050101

• New drugs for colorectal cancer (irinotecan, oxaliplatin, raltitrexed) meet expectations in routine practice: a single center's experience before and after their introduction.

  International journal of gastrointestinal cancer 20050101

• First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study.

  Oncology 20050101

• Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer.

  Anticancer research 20050101

• A phase II trial of raltitrexed (Tomudex) in advanced pancreatic and biliary carcinoma.

  Oncology 20050101

• Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.

  BMC cancer 20050101

• Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).

  Anticancer research 20050101

• Survival after oxaliplatin therapy of irinotecan-pretreated advanced colorectal cancer patients.

  Hepato-gastroenterology 20050101

• Raltitrexed and radiotherapy as adjuvant treatment for stage II-III rectal cancer: a feasibility study.

  Tumori 20050101

• Raltitrexed increases tumorigenesis as a single agent yet exhibits anti-tumor synergy with 5-fluorouracil in ApcMin/+ mice.

  Cancer biology & therapy 20041101

• Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.

  British journal of cancer 20041018

• A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.

  British journal of cancer 20041018

• Epirubicin, cisplatin, and raltitrexed in patients with advanced gastric and hepatobiliary carcinoma: a phase II study.

  American journal of clinical oncology 20041001

• Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040915

• A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile.

  Virchows Archiv : an international journal of pathology 20040901

• Chemoradiation with raltitrexed (Tomudex) in preoperative treatment of stage II-III resectable rectal cancer: a phase II study.

  International journal of radiation oncology, biology, physics 20040901

• Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies.

  International journal of radiation oncology, biology, physics 20040901

• Thymidylate synthase: a critical target in cancer therapy?

  Frontiers in bioscience : a journal and virtual library 20040901

• UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.

  British journal of cancer 20040816

• Chemotherapy for malignant pleural mesothelioma: past results and recent developments.

  Lung cancer (Amsterdam, Netherlands) 20040801

• p14ARF expression increases dihydrofolate reductase degradation and paradoxically results in resistance to folate antagonists in cells with nonfunctional p53.

  Cancer research 20040615

• Involvement of base excision repair in response to therapy targeted at thymidylate synthase.

  Molecular cancer therapeutics 20040601

• Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.

  British journal of cancer 20040517

• The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040515

• Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway.

  Cancer research 20040501

• Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study.

  British journal of cancer 20040419

• Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.

  British journal of clinical pharmacology 20040401

• A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040301

• Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer.

  Anti-cancer drugs 20040301

• Structural determinants for the intracellular degradation of human thymidylate synthase.

  Biochemistry 20040224

• Small interfering double-stranded RNAs as therapeutic molecules to restore chemosensitivity to thymidylate synthase inhibitor compounds.

  Cancer research 20040215

• The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040201

• Effects of ligand binding and conformational switching on intracellular stability of human thymidylate synthase.

  Biochimica et biophysica acta 20040114

• Cancer pharmacogenetics.

  British journal of cancer 20040112

• Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma.

  British journal of cancer 20040112

• Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy.

  Drugs & aging 20040101

• Treatment of colorectal cancer metastasis: the role of chemotherapy.

  Cancer metastasis reviews 20040101

• Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii study.

  Medical oncology (Northwood, London, England) 20040101

• 5-Fluorouracil: identification of novel downstream mediators of tumour response.

  Anticancer research 20040101

• Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma.

  Anticancer research 20040101

• Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer.

  Tumori 20040101

• Efficacy of infusional biomodulated 5-fluorouracil in metastatic colorectal cancer after raltitrexed failure.

  Anticancer research 20040101

• Neoadjuvant therapy of rectal cancer new treatment perspectives.

  Tumori 20040101

• Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.

  Oncology 20040101

• Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C.

  British journal of cancer 20031215

• Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma.

  British journal of cancer 20031117

• Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.

  British journal of cancer 20031020

• Review article: colorectal cancer chemotherapy.

  Alimentary pharmacology & therapeutics 20031001

• A new nonlinear mixture response surface paradigm for the study of synergism: a three drug example.

  Current drug metabolism 20031001

• Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma.

  British journal of cancer 20030915

• Hypersensitivity reactions related to oxaliplatin (OHP).

  British journal of cancer 20030804

• Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells.

  International journal of oncology 20030801

• Intestinal permeability in colorectal cancer patients treated by raltitrexed or irinotecan.

  Journal of clinical gastroenterology 20030801

• Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.

  Biochemical pharmacology 20030801

• Lessons learned from raltitrexed--quality assurance, patient education and intensive supportive drugs to optimise tolerability.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20030801

• Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors.

  Anti-cancer drugs 20030801

• Thymidylate synthase inhibitors as anticancer agents: from bench to bedside.

  Cancer chemotherapy and pharmacology 20030701

• Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030701

• Treatment of advanced gastric cancer: where we are in 2003.

  Onkologie 20030601

• Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed.

  Onkologie 20030601

• Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil.

  British journal of cancer 20030519

• [Malignant pleural mesothelioma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030501

• Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.

  British journal of cancer 20030422

• Combination chemotherapy for advanced colorectal cancer.

  British journal of cancer 20030407

• Raltitrexed plus radiotherapy for the treatment of unresectable/recurrent rectal cancer: a phase I study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030401

• Activity of raltitrexed and gemcitabine in advanced pancreatic cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030401

• A 'combination oligonucleotide' antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance.

  Cancer gene therapy 20030401

• Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy.

  British journal of cancer 20030324

• EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.

  British journal of cancer 20030310

• Novel antifolate drugs.

  Current oncology reports 20030301

• [Severe acute cytomegalovirus colitis after administration of irinotecan and raltitrexed chemotherapy].

  Gastroenterologie clinique et biologique 20030301

• Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells.

  British journal of cancer 20030224

• Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.

  Lancet (London, England) 20030208

• The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).

  European journal of cancer (Oxford, England : 1990) 20030201

• Expression of uracil DNA glycosylase (UDG) does not affect cellular sensitivity to thymidylate synthase (TS) inhibition.

  European journal of cancer (Oxford, England : 1990) 20030201

• Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030201

• [Economic assessment of adjuvant and palliative chemotherapy in colorectal cancer: a review].

  Bulletin du cancer 20030201

• [Chemotherapy for colorectal cancers].

  Journal de chirurgie 20030201

• Chemotherapy for malignant pleural mesothelioma: past results and recent developments.

  British journal of cancer 20030127

• Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030115

• Detection of thymidylate synthase modulators by a novel screening assay.

  Molecular pharmacology 20030101

• Pharmacokinetics studies and toxicity profile of raltitrexed used by intraperitoneal route in normothermia in a pig model.

  Medical science monitor : international medical journal of experimental and clinical research 20030101

• Severe liver dysfunction after raltitrexed administration in an HCV-positive colorectal cancer patient.

  Cancer investigation 20030101

• Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study.

  Anticancer research 20030101

• Palliative treatment of patients with colorectal cancer.

  Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society 20030101

• Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030101

• [Experience in treating elderly patients with disseminated stomach and colon cancer].

  Advances in gerontology = Uspekhi gerontologii 20030101

• [Early evaluation using PET-FDG of the efficiency of neoadjuvant radiochemotherapy treatment in locally advanced neoplasia of the lower rectum].

  Tumori 20030101

• Favorable toxicity profile of raltitrexed in elderly patients treated for colorectal cancer: a case series.

  Gerontology 20030101

• Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study.

  Anticancer research 20030101

• Anticancer antifolates: current status and future directions.

  Current pharmaceutical design 20030101

• New developments in systemic chemotherapy in advanced colorectal cancer.

  Scandinavian journal of gastroenterology. Supplement 20030101

• Up-regulation in dihydropyrimidine dehydrogenase activity by raltitrexed causes antagonism in combination with 5-fluorouracil.

  Anticancer research 20030101

• The rational principles of neo-adjuvant therapy for rectal cancer.

  Acta bio-medica : Atenei Parmensis 20030101

• Identification of lysine-411 in the human reduced folate carrier as an important determinant of substrate selectivity and carrier function by systematic site-directed mutagenesis.

  Biochimica et biophysica acta 20021223

• The raltitrexed-vinorelbine combination: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer.

  Cancer chemotherapy and pharmacology 20021201

• Role of the E45K-reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells.

  Leukemia 20021201

• Emerging insights into the biology and therapy of malignant mesothelioma.

  Seminars in oncology 20021201

• Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.

  British journal of cancer 20021118

• [New therapeutic options for mesothelioma].

  Revue de pneumologie clinique 20021101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021101

• Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.

  Cancer chemotherapy and pharmacology 20021001

• Oxaliplatin: results in colorectal carcinoma.

  Critical reviews in oncology/hematology 20021001

• Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.

  British journal of cancer 20020909

• Irinotecan and raltitrexed: an active combination in advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020901

• Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.

  Urological research 20020901

• Effects of antifolates on the binding of 5-fluoro-2'-deoxyuridine monophosphate to thymidylate synthase.

  Biochemical pharmacology 20020815

• The means to an end of tumor cell resistance to chemotherapeutic drugs targeting thymidylate synthase: shoot the messenger.

  Current drug targets 20020801

• Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial.

  Anti-cancer drugs 20020801

• Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen.

  Onkologie 20020801

• Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: a concern about dose.

  Clinical colorectal cancer 20020801

• A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.

  Biochimica et biophysica acta 20020718

• Baseline quality of life predicts survival in patients with advanced colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20020701

• Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020701

• Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients.

  British journal of cancer 20020617

• Why hasn't the National Institute been 'NICE' to patients with colorectal cancer? National Institute of Clinical Excellence.

  British journal of cancer 20020605

• Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?

  British journal of cancer 20020605

• Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer.

  British journal of cancer 20020605

• Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen.

  European journal of cancer (Oxford, England : 1990) 20020601

• Advanced colorectal cancer treatment in Europe: what have we achieved?

  Anti-cancer drugs 20020601

• Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics.

  Journal of chemotherapy (Florence, Italy) 20020601

• Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.

  Lancet (London, England) 20020504

• Phase I dose-escalating study of raltitrexed ('Tomudex') and cisplatin in metastatic non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20020501

• Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).

  Annals of oncology : official journal of the European Society for Medical Oncology 20020501

• Pemetrexed for diffuse malignant pleural mesothelioma.

  Seminars in oncology 20020401

• Raltitrexed: current clinical status and future directions.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020401

• Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer.

  British journal of cancer 20020304

• Combined chemotherapy trials require combined pharmacogenetic approaches.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020301

• Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.

  European journal of cancer (Oxford, England : 1990) 20020301

• Update on pharmacogenetics in cancer chemotherapy.

  European journal of cancer (Oxford, England : 1990) 20020301

• The emerging role of antifolates in the treatment of malignant pleural mesothelioma.

  Seminars in oncology 20020201

• Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma.

  British journal of cancer 20020201

• Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study.

  Investigational new drugs 20020201

• Thymidylate synthase: a critical target for cancer chemotherapy.

  Clinical colorectal cancer 20020201

• [The new chemotherapy of colorectal cancers].

  Presse medicale (Paris, France : 1983) 20020126

• Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.

  Biochemical pharmacology 20020115

• Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020101

• Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020101

• Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.

  BMC cancer 20020101

• Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011.

  Anti-cancer drugs 20020101

• Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.

  Oncology 20020101

• Raltitrexed as monochemotherapy induces a statistically significant increase in platelet count.

  Acta oncologica (Stockholm, Sweden) 20020101

• Conjoint analysis of a new Chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced Colorectal Cancer.

  PharmacoEconomics 20020101

• [The rare manifestation of soft tissue metastasis in colorectal cancer].

  Magyar onkologia 20020101

• Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.

  Oncology 20020101

• Chemotherapy in colorectal cancer: new options and new challenges.

  British medical bulletin 20020101

• [Raltitrexed and oxaliplatin in colorectal cancer: in vitro and in vivo study of a synergistic cytostatic combination].

  Acta medica Austriaca 20020101

• Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil.

  Cancer investigation 20020101

• Tolerability of Raltitrexed ('Tomudex') in elderly patients with colorectal cancer.

  Anticancer research 20020101

• A potential important role for thymidylate synthetase inhibition on antitumor activity of fluoropyrimidine and raltitexed.

  Anticancer research 20020101

• New cytotoxic agents and molecular-targeted therapies in the treatment of metastatic breast cancer.

  Forum (Genoa, Italy) 20020101

• Oxaliplatin: available data in non-colorectal gastrointestinal malignancies.

  Critical reviews in oncology/hematology 20011201

• Metastatic colorectal cancer.

  Current treatment options in oncology 20011201

• Preoperative chemoradiation with raltitrexed ('Tomudex') for T2/N+ and T3/N+ rectal cancers: a phase I study.

  European journal of cancer (Oxford, England : 1990) 20011101

• Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011101

• Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011101

• Thymidylate synthase pharmacogenetics in colorectal cancer.

  Clinical colorectal cancer 20011101

• Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20011015

• [New therapeutic options in chemotherapy of advanced colorectal cancer].

  Medizinische Klinik (Munich, Germany : 1983) 20011015

• A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20011001

• [Recent aspects of palliative treatment of metastasized colorectal carcinoma].

  Medizinische Klinik (Munich, Germany : 1983) 20010915

• Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010901

• Antifolate resistance and its circumvention by new analogues.

  Human cell 20010901

• Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer.

  International journal of oncology 20010801

• [Oxaliplatin: a first DACH-platinum in oncology].

  Bulletin du cancer 20010801

• [Oxaliplatin in combination with non fluoropyrimidine drugs in colorectal cancer].

  Bulletin du cancer 20010801

• [New aspects in chemotherapy of tumors of the digestive tract].

  Vnitrni lekarstvi 20010801

• Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.

  Cancer research 20010715

• The impact of p53 status on cellular sensitivity to antifolate drugs.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010701

• Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy.

  Anti-cancer drugs 20010701

• Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20010501

• Crystal structure of a deletion mutant of human thymidylate synthase Delta (7-29) and its ternary complex with Tomudex and dUMP.

  Protein science : a publication of the Protein Society 20010501

• Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.

  Cancer research 20010501

• Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells.

  Cell death and differentiation 20010501

• Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd).

  Annals of oncology : official journal of the European Society for Medical Oncology 20010501

• Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010501

• New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.

  The Lancet. Oncology 20010501

• Advances in the treatment of metastatic colorectal cancer.

  Clinical colorectal cancer 20010501

• Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells.

  Biochemical pharmacology 20010401

• Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial.

  Cancer 20010401

• The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.

  Oncology (Williston Park, N.Y.) 20010401

• Chemotherapy in elderly patients with colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010401

• Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010401

• [New chemotherapies for colorectal cancer treatment].

  Gastroenterologie clinique et biologique 20010401

• A novel approach to thymidylate synthase as a target for cancer chemotherapy.

  Molecular pharmacology 20010301

• Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis.

  Gastroenterology 20010301

• A phase I study of a fixed dose of cisplatin with increasing doses of raltitrexed (Tomudex) in the treatment of patients with locally advanced or metastatic squamous cell carcinoma of the head and neck.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010301

• Human thymidylate synthase is in the closed conformation when complexed with dUMP and raltitrexed, an antifolate drug.

  Biochemistry 20010220

• Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010201

• [Non-alcoholic steatohepatitis with cirrhosis after raltitrexed administration].

  Gastroenterologie clinique et biologique 20010201

• Inhibition of thymidine synthesis by folate analogues induces a Fas-Fas ligand-independent deletion of superantigen-reactive peripheral T cells.

  International immunology 20010101

• The anticytomegaloviral activity of raltitrexed is abrogated in quiescent mouse fibroblasts that overexpress thymidylate synthase.

  Virus research 20010101

• Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.

  Clinical and experimental immunology 20010101

• Schedule-dependent synergism and antagonism between raltitrexed ('Tomudex') and methotrexate in human colon cancer cell lines in vitro.

  Japanese journal of cancer research : Gann 20010101

• Retroviral expression of Escherichia coli thymidylate synthase cDNA confers high-level antifolate resistance to hematopoietic cells.

  Human gene therapy 20010101

• Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.

  Cancer chemotherapy and pharmacology 20010101

• [Raltitrexed in colorectal cancer].

  Tumori 20010101

• Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer.

  Drug safety 20010101

• Molecular and cellular biology of the human reduced folate carrier.

  Progress in nucleic acid research and molecular biology 20010101

• A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer.

  Oncology 20010101

• Characterization and drug sensitivity of four newly established colon adenocarcinoma cell lines to antifolate inhibitors of thymidylate synthase.

  Oncology research 20010101

• [Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial].

  Gastroenterologie clinique et biologique 20010101

• [Irinotecan and tomudex in the treatment of patients with advanced cancer of the large intestine].

  Voprosy onkologii 20010101

• Present indications for adjuvant therapy in resectable rectal cancer.

  Annali italiani di chirurgia 20010101

• [Intraoperative radiotherapy (IORT) in the treatment of rectal cancer].

  Annali italiani di chirurgia 20010101

• Oxaliplatin and raltitrexed in the treatment of inoperable malignant pleural mesothelioma: results of a pilot study.

  Tumori 20010101

• A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.

  Health technology assessment (Winchester, England) 20010101

• [Oxaliplatin: combinations with thymidylate synthetase inhibitors: two consecutive phase II studies].

  Tumori 20010101

• [Colorectal cancer: irinotecan in combination with newer drugs].

  Tumori 20010101

• The thymidylate synthase inhibitor ZD1694 potently inhibits murine and human cytomegalovirus replication in quiescent fibroblasts.

  Antiviral research 20000801

• Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells.

  British journal of pharmacology 19990801

• Syntheses and thymidylate synthase inhibitory activity of the poly-gamma-glutamyl conjugates of N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino ]-2-thenoyl]-L-glutamic acid (ICI D1694) and other quinazoline antifolates.

  Journal of medicinal chemistry 19920306

• The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice.

  British journal of cancer 19911101